The company also confirmed GAAP EPS and non-GAAP EPS guidance ranges for 2013.
The company also confirmed GAAP EPS and non-GAAP EPS guidance ranges for 2013. ‘In the third one fourth, we demonstrated solid financial performance and presented brand-new medical data further characterizing essential brands from our immuno-oncology and diabetes franchises,’ said Lamberto Andreotti, ceo, Bristol-Myers Squibb. ‘As we continue to execute against our technique today, we remain centered on investing in the meaningful possibilities that may drive the long-term development of our organization http://www.methan-d.com .’ Financial outcomes Bristol-Myers Squibb published third quarter 2013 net sales of $4.1 billion, a rise of 9 percent compared to the same period a full 12 months ago.
dianabol for sale
The DCV NDA also seeks authorization for use of this compound in combination with other agents for multiple genotypes. The submissions are subject to FDA review for acceptance for submitting. An interview with Dr Chhatwal These FDA submissions represent a significant stage towards offering daclatasvir-centered regimens to U.S. HCV sufferers, many of whom continue steadily to possess high unmet medical needs, stated Brian Daniels, MD, senior vice president, Global Development and Medical Affairs, Development and Research, Bristol-Myers Squibb. We are excited to have attained this milestone and, looking forward, will continue steadily to innovate and spend money on daclatasvir in a variety of individual regimens and types.